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ADCC: Antibody-dependent cellular cytotoxicity 37 
AEC: Aminoethyl-carbazole 38 
APC: Allophycocyanine 39 
BV: Brilliant Violet 40 
CMV: Cytomegalovirus  41 
CyTOF: Mass cytometry 42 
EBV: Epstein-Barr-Virus 43 
EDTA: Ethylenediaminetetraacetic acid 44 
EPCR: Endothelial protein C receptor 45 
Er: Erbium 46 
FITC: Fluorescein isiothiocyanate 47 
Gd: Gadolinium 48 
IHC: Immunohistochemistry 49 
Ir: Iridium 50 
Monoclonal antibody: mAb 51 
PBMC: Peripheral blood mononuclear cell 52 
PBS: Phosphate-buffered saline 53 
PE: Phycoerythrin 54 
PHA-L: Phytohemagglutinin-L 55 
PI: Positive isolation 56 
PMA: Phorbol 12-myristate 13-acetate 57 
Pr: Praseodymium 58 
Sm: Samarium 59 





Dissection of the role and function of human γδ T cells and their heterogeneous subsets 62 
in cancer, inflammation and auto-immune diseases is a growing and dynamic research 63 
field of increasing interest to the scientific community. Therefore, harmonization and 64 
standardization of techniques for the characterization of peripheral and tissue-resident 65 
γδ T cells is crucial to facilitate comparability between published and emerging research. 66 
The application of commercially-available reagents to classify γδ T cells, in particular the 67 
combination of multiple antibodies, is not always trouble-free, posing major demands on 68 
researchers entering this field. Occasionally, even entire γδ T cell subsets may remain 69 
undetected when certain antibodies are combined in flow cytometric analysis with 70 
multicolor antibody panels, or might be lost during cell isolation procedures. Here, based 71 
on the recent literature and our own experience, we provide an overview of methods 72 
commonly employed for the phenotypic and functional characterization of human γδ T 73 
cells including advanced polychromatic flow, mass cytometry, immunohistochemistry 74 
and magnetic cell isolation. We highlight potential pitfalls and discuss how to circumvent 75 
these obstacles. 76 
 77 





Knowledge of the orchestration of γδ T cells in the ensemble of immunity is still limited, 80 
especially in humans. These “unconventional” T cells are a numerically minor population 81 
in peripheral blood, representing 1-10% of all T cells and are, unlike αβ T cells, not 82 
MHC-restricted [1]. Knowledge of γδ T cell receptor (TCR) ligands is sparse; only a few, 83 
structurally diverse molecules such as phosphoantigens, CD1, endothelial protein C 84 
receptor (EPCR) and other cell-surface structures have been identified [2], suggesting 85 
an immense potential for diversity. The γδ T cell population comprises heterogeneous 86 
subsets with various functions including secretion of cytokines such as TNF, IFN-γ and 87 
IL-17 [3], cytotoxic activity via the granzyme-perforin axis and antibody-dependent 88 
cellular cytotoxicity (ADCC) by CD16 expressing cells [4], antigen-presentation functions 89 
[5] and interactions with B cells promoting immunoglobulin class switching [6]. Vδ1 γδ T 90 
cells are the predominant T cell subset in some tissues, accounting for around 40% of all 91 
intra-epithelial lymphocytes in the large intestine, for example [7]. The Vδ1 TCR 92 
repertoire is often private, highly focused on a few clones, and displays features of the 93 
adaptive immune system [8]. On the other hand, Vδ2 γδ T cells, which dominate the γδ 94 
TCR repertoire in peripheral blood, have a semi-invariant TCR, a diverse public 95 
repertoire and mainly behave in an innate-like manner [9]. Due to their pleiotropic roles 96 
in immunity and implications in cancer, infectious and auto-immune diseases, γδ T cells 97 
are of rapidly growing interest. Transcriptomic analyses have documented that intra-98 
tumoral γδ T cells may represent significant favorable prognostic immune cell 99 
populations in several different cancers [10] and Oberg et al. observed large numbers of 100 
different γδ T cell subsets infiltrating isolated pancreatic and ovarian tumors ex vivo  [11, 101 




contribute to the immune response against CMV [13, 14] and malaria [15], and to be 103 
involved in various inflammatory conditions [16]. It is therefore important to harmonize 104 
and standardize techniques for the investigation of γδ T cells in order to avoid potential 105 
pitfalls when using and combining commercially-available antibodies and comparing 106 
results between centers. Here, we aim to provide a basic framework for the phenotypic 107 
and functional characterization of peripheral and tissue-resident γδ T cells, including 108 
magnetic cell isolation, advanced polychromatic flow cytometry, mass cytometry 109 
(CyTOF) and immunohistochemistry (IHC).  110 
 111 




Material and Methods 113 
Study participants and sample acquisition 114 
Blood samples were obtained from healthy adult volunteers at the Department of 115 
Hematology and Oncology, Children’s Hospital, University of Tübingen (Project no. 116 
38/2009BO2, 470/2013BO2, 673/2015BO2, 105/2017BO2 and 880/2017BO2) and from 117 
the biobank at the Interfaculty Institute of Cell Biology (IFIZ), Department of immunology, 118 
University of Tübingen (Project no. 156/2012BO1 and 633/2019BO2). Tissue samples 119 
from patients with EBV-associated Hodgkin’s lymphoma (with pathological features 120 
assessed according to the WHO classification) and colon carcinoma (staged according 121 
to the UICC TNM classification system) were obtained at the University Hospital 122 
Schleswig-Holstein, Kiel (D430/09). Written informed consent was obtained from all 123 
blood and tissue donors. This study was conducted in accordance with the Declaration 124 
of Helsinki and applicable laws and regulations, and has been approved by the 125 
respective institutional review boards (Ethics Committees at the University Hospital 126 
Schleswig-Holstein in Kiel and at the University Hospital Tübingen). 127 
 128 
Magnetic cell isolation  129 
γδ T cells were isolated from fresh peripheral blood mononuclear cells (PBMCs) via 130 
magnetic cell isolation using the following commercial kits: i) Immunomagnetic negative 131 
selection cell isolation kit: TCRγ/δ+ T Cell Isolation Kit Human (Miltenyi Biotec) or 132 
Immunomagnetic negative selection cell isolation kit: EasySep™ Human Gamma/Delta 133 
T Cell Isolation Kit (STEMCELL Technologies) or, as we show in Figure 1, customized 134 




positive selection was performed with a fluorochrome-labelled Vδ2-specific antibody 136 
(clone B6, BD) and for secondary labelling and anti-fluorochrome sorting, either anti-137 
FITC Micro-beads (Miltenyi Biotec) or anti-PE MicroBeads Ultra Pure (Miltenyi Biotec) or 138 
an Immunomagnetic positive selection kit EasySep™ PE Positive Selection Kit II 139 
(STEMCELL Technologies) were used. 140 
 141 
Polychromatic flow cytometry 142 
Phenotypic and functional analysis followed standardized protocols on cryopreserved 143 
samples. For immunomonitoring studies, cryopreservation is still the gold standard to 144 
minimize bias introduced by batch to batch variance in polychromatic flow cytometry, 145 
although the expression pattern of some particular markers may be affected. In brief, 146 
peripheral blood was drawn and anticoagulated using EDTA, followed by Ficoll-Hypaque 147 
density gradient centrifugation to isolate PBMCs. After washing twice, the cells were 148 
cryopreserved in medium with 10% DMSO and 20% FCS in RPMI-1640 and stored at -149 
196oC. Cryopreserved PBMCs were thawed, incubated with an Fc-receptor-blocking 150 
reagent (Gammunex, Grifols) and ethidium monoazide (EMA, Biotium) or LIVE/DEAD 151 
fixable red (Thermo Fisher Scientific) to label dead cells. Next, characteristic cell surface 152 
antigens of γδ T cells were stained using the following monoclonal antibodies (mAbs) to 153 
illustrate various common panel compositions: CD3 Alexa Fluor 700 and CD3 BV510 154 
(both clone UCHT1, Biolegend), pan-γδ TCR Biotin (clone 11F2, Miltenyi Biotec), pan-γδ 155 
TCR FITC (clone 11F2, BD), pan-γδ TCR purified and pan-γδ TCR PE (both clone 156 
IMMU510, Beckman Coulter), Vδ1 TCR FITC, Vδ1 TCR PerCP-Vio700 and Vδ1 TCR 157 




TCR PE and Vδ2 TCR FITC (both clone 123R3, Miltenyi Biotec), Streptavidin-PE 159 
(Biolegend), F(ab')2-Fragment goat anti mouse Pacific Orange (Invitrogen). For 160 
characterization of established T cell clones, antibodies against Vγ2/3/4 (clone 23D12) 161 
[17], Vγ3/5 (clone 56.3) [18] and pan-αβ TCR FITC (clone IP26, Biolegend) were used. 162 
The generation of 56.3+ T cell clones has been described previously. In brief, 56.3 163 
positive cells were selected by MACS from PBMCs from healthy donors and were 164 
cloned at 0.3 cells per well in the presence of irradiated feeder cells, PHA 0.5 µg/mL and 165 
IL-2 (50 IU) [18].  166 
For intracellular staining, cryopreserved PBMCs that had been stimulated with PMA (20 167 
ng/ml, Sigma) and Ionomycin (750 ng/ml, Merck) or Zoledronate (5 µM, Hexal) and 168 
incubated with Brefeldin A (GolgiPlug, BD), Monensin (GolgiStop, BD) and CD107a 169 
Pacific Blue (clone H4A3, Biolegend) for 12h, were fixed and permeabilized using a 170 
fixation/permeabilization solution kit (BD) and stained with the following antibodies: IFN-171 
γ PE-Cy7 (clone B27, Biolegend), IL-17A BV711 (clone BL168, Biolegend), TNF-α Alexa 172 
Fluor 700 (clone Mab11, Biolegend). Proliferation in response to stimulation with PHA-L 173 
(Roche) was tracked by labelling cells with CellTraceViolet (Thermo Fisher Scientific). 174 
Optimal results were achieved when seeding 0.2x106 cells in 200 µL medium per well in 175 
96-well U bottom plates (Greiner). Proportional upscaling, e.g. seeding 0.6x106 cells in 176 
600µl medium in a 48-well plate, was possible though not optimal, enabling analysis of 177 
donors with low percentages of γδ T cells, patient samples and subpopulations. Panels 178 
for functional analysis and for tracking of proliferation are summarized in Table 1. Data 179 
were acquired using a three laser LSR II (BD) with FACSDiva software V6.1.3 (BD) and 180 
customized filter settings and data analysis was performed with FlowJo V10.5.3 (BD; 181 




Mass cytometry 183 
Mass cytometric analysis followed established protocols [19]. In brief, cryopreserved 184 
PBMCs were thawed, dead cells were stained with Rhodium 103 and cell surface Fc 185 
receptors were blocked. Samples were then incubated with an antibody cocktail for cell 186 
surface staining which contained antibodies against CD3 170Er (clone UCTH1, 187 
Fluidigm), pan-γδ TCR 152Sm (clone 11F2, Fluidigm), Vδ2 TCR141Pr (clone B6, 188 
Biolegend; in house-conjugated, using Fluidigm´s Maxpar antibody labelling kit; catalog 189 
no.: 201141B) and Vδ1 TCRFITC (clone TS8.2, Thermo Fisher Scientific) amongst 190 
others. Next, an anti-FITC 160Gd antibody (Fluidigm) was used to stain Vδ1 T cells. 191 
After fixation, permeabilization and staining of intracellular antigens, samples were 192 
incubated for at least 12 hours in a solution of 4% paraformaldehyde in PBS. Samples 193 
were stained in batches with 125Ir on the mornings of the respective days of data 194 
acquisition. Each sample was rebuffered in purified water directly before acquisition on a 195 
Helios system (Fluidigm) at King´s College London. Data analysis was performed with 196 
FlowJo V10.5.3 (BD). 197 
 198 
Immunohistochemistry 199 
Immunostaining with mAbs against γδ TCR (clone γ3.20, Thermo Fisher Scientific), Vγ9 200 
TCR (clone 7A5) [20], Vγ2/3/4 TCR (clone 23D12) [17, 18] or mouse IgG1 isotype 201 
control (Thermo Fisher) of serial paraffin-embedded tissue sections from patients with 202 
EBV-associated Hodgkin’s lymphoma was carried out after deparaffinization with the 203 
fully automated Bond Max-system using the Bond Polymer Refine Detection Kit (Leica-204 




Solution 1 (citrate buffer pH 6.0; Leica-Menarini).  Additionally, immunostaining with 206 
Vγ2/3/4 TCR (clone 23D12), Vδ1 TCR (clone R3.12, Beckman Coulter) or mouse IgG1 207 
isotype control of cryopreserved sections from patients with colon carcinoma was done 208 
after acetone fixation and blockade with 4% bovine serum albumin. As second step, 209 
antibody EnVision mouse horseradish peroxidase (DAKO) was used. The substrate 210 
reaction was performed using the AEC substrate for peroxidase (DAKO). Finally, 211 




Results and Discussion 213 
 214 
Magnetic isolation of γδ T cells and subsets 215 
Isolation of γδ T cells is a critical procedure and the methodology of choice needs to be 216 
adapted to the design of each particular experiment. The total γδ T cell compartment 217 
can be positively or negatively selected using kits from commercial suppliers (e.g. 218 
Miltenyi Biotec and STEMCELL Technologies) (Figure 1A, 1B). In addition to beads 219 
directly coupled to a γδ TCR-targeting antibody (Miltenyi Biotec), secondary labelling 220 
strategies allow sorting and discriminating γδ T cell subsets. Multi-sort beads facilitate 221 
multiple rounds of positive selection because these labels can be removed. Positive 222 
isolation (PI) is suitable for separating aminobisphosphonate-expanded γδ T cells or γδ 223 
T cells expressing particular Vγ/Vδ elements from PBMCs (Figure 1B), and γδ T cells 224 
from intra-tumoral lymphoid compartments, e.g. for TCR sequence analysis, offering the 225 
advantage of sparing other (infiltrating) cells for further isolation/analysis. On the other 226 
hand, for studies examining cell activation status, receptor signaling, cytokine 227 
expression and/or cytotoxicity, γδ T cells should be negatively selected to avoid 228 
antibody-cross-linking of the γδ TCR. Although some manufacturers claim that immune 229 
cells experience no activation through their PI procedure, γδ T cells do upregulate CD69 230 
after PI [21] and show significant functional bias compared to negatively selected cells 231 
from the same donor. The EasySep™ Human Gamma/Delta T Cell Isolation Kit from 232 
STEMCELL Technologies removes non-γδ T cells with tetrameric antibody complexes 233 
and dextran-coated magnetic particles by retaining them inside a tube using a strong 234 
magnetic field. Whereas labelled cells remain attached to the tube wall, the remaining 235 




Biotec’s biotin-conjugated depletion cocktail eliminates non-γδ T cells via a secondary 237 
magnetic label that retains them on a “MACS® Column” in a magnetic field. High purities 238 
– above 98.5% γδ T cells – are routinely achieved with both methods independent of the 239 
initial content of γδ T cells and obtained isolates do not contain any undesired αβ T cells 240 
(Fig. 1A). The “untouched” negatively-sorted cells are not activated. The STEMCELL 241 
Technologies procedure is faster and yields remain quantitative, even when drastically 242 
downscaling initial cell numbers (due to zero dead space volume). Moreover, 243 
physiological stressors such as mechanical stress, centrifugal forces, and extensive 244 
incubation at unphysiologically low temperatures during labelling and purification are 245 
avoided. 246 
Pitfalls that may be encountered, when using either of these negative selection 247 
procedures are: i) depleted cells are heavily labelled and can not be used for further 248 
downstream applications; ii) depletion cocktails often contain antibodies targeting 249 
molecules also expressed by subpopulations of γδ T cells, e.g. CD16, which may 250 
severely bias subsequent (functional) studies, such as ADCC or gene expression 251 
analyses. We therefore suggest the use of anti-NKp46 (a lineage marker of NK cells) 252 
and anti-NKp30 instead of anti-CD16 for NK-cell elimination during negative γδ T cell 253 
isolation. NKp46 and NKp30 are expressed on peripheral NK cells but not on γδ T cells 254 
in the peripheral blood. However, it should be noted that long-term activation of γδ T 255 
cells induces the expression of NKp46, NKp30 and also of Nkp44 in certain subsets 256 
(Supplementary Figure 2) [22]. Until commercial kits that exclude anti-human CD16 257 
mAbs become available customized kits are an option.  258 
When aiming to negatively isolate specific subsets of γδ T cells, a combination of 259 




other γδ T cell subsets such as Vδ3 γδ T cells must be removed (via PI) before γδ T cell 261 
negative selection yields the Vδ2 T cell subset isolate. Unless an anti-human Vδ3 mAb 262 
is available, individuals with high numbers of Vδ1-Vδ2- γδ T cells are not suitable for Vδ2 263 
negative selection (Figure 1C). A potential candidate for this approach might be the 264 
monoclonal anti-human T cell receptor Vδ3 antibody (clone P11.5B), which was 265 
previously distributed by Gentaur and Coulter. However, at the time of writing, the 266 
commercial availability of this antibody, its format and thus its suitability for magnetic cell 267 
isolation remain unclear.  268 
 269 
Phenotypic and functional analysis via polychromatic flow cytometry 270 
When designing an antibody panel for multicolor flow cytometry a few considerations 271 
need to be taken into account, in order to avoid certain γδ T cell subsets remaining 272 
undetected, and thus biasing subsequent analysis. Below, we aim to highlight the 273 
commonest problems and to provide a framework for the flow cytometric analysis of γδ T 274 
cells. Furthermore, we briefly present panels designed for the investigation of phenotypic 275 
markers, as well as functional and proliferative properties. 276 
We previously reported that the unconjugated pan-γδ TCR antibody clone 11F2 was the 277 
only tested antibody able to detect all γδ T cells when combined with a Vδ2 antibody 278 
(B6, IMMU389), while the conjugated forms of the commercially-available clones 11F2, 279 
B1/B1.1 do not always stain 100% of the γδ T cell population [23]. Moreover, clone 280 
B1/B1.1 is unsuitable for multicolor flow cytometry panels including a CD3 antibody due 281 
to interference between these two antibodies [23]. The recently-developed generation of 282 
γδ TCR subset-specific antibodies, namely Vδ1 clone REA173 and Vδ2 clone 123R3 in 283 




flow cytometric characterization of γδ T cells (Figure 2A), overcoming the above-285 
mentioned issues (Supplementary Figure 3A). We tested directly fluorophore-labelled 286 
and secondarily detected pan-γδ TCR antibodies (11F2 and IMMU510) to achieve an 287 
optimal balance between a rapid and straightforward staining protocol, low background 288 
signal and a high staining index (Figure 2B). Separation of the γδ T cell population via 289 
directly-labelled pan-γδ TCR antibodies (11F2, IMMU510) can be problematic in the 290 
detection of Vδ1 T cells with low surface TCR expression levels (Supplementary Figure 291 
3B) as seen in patient samples or in in vitro culture systems. Detection of the purified 292 
formats of these antibodies via fluorophore-labelled anti-mouse antibodies is generally 293 
not preferable due to prolonged staining procedures and high background signals. We 294 
identified the biotinylated 11F2 clone as an optimal choice (Figure 2A, 2B), because the 295 
biotin/streptavidin detection system combines signal amplification with simultaneously 296 
low background, resulting in improved separation of the target population, especially in 297 
fixed cells (Supplementary Figure 3C). The prolonged staining protocol (1) pan-γδ TCR, 298 
(2) streptavidin conjugate, (3) surface antibody cocktail can be reduced by integration of 299 
the streptavidin conjugate into the antibody master mix for extracellular staining. In 300 
general, use of PE-conjugates for pan γδ T cell antibodies is recommended, because 301 
PE itself is recognized by certain γδ TCRs and thus stains a small percentage of 302 
peripheral γδ T cells [24]. This should also be kept in mind when tandem conjugates 303 
containing PE (e.g. PE-Cy7, PE-Cy5.5 etc.) are included in the antibody panel. As stated 304 
above, the Vδ2 123R3 antibody is, in contrast to clone B6, compatible with fluorophore-305 
conjugated pan-γδ TCR antibodies. Of note, clone B6 might be specific for the Vγ9Vδ2 306 




not possible with clone B6, but clone 123R3 can be used as an alternative to also detect 308 
the rare population of Vγ9−Vδ2+ T cells [9].  309 
On the basis of this framework for detection of γδ T cells, we developed several 310 
polychromatic antibody panels: i) a phenotypic γδ T cell panel including markers for 311 
differentiation state [23] ii) a panel to monitor functionality of γδ T cells including the 312 
degranulation marker CD107a and the cytokines TNF, IFN-γ and IL-17A (Figure 3A) and 313 
iii) a panel to track γδ T cell proliferative capacity using CellTraceViolet (Figure 3B). The 314 
above-described basic phenotypic markers (pan-γδ TCR, Vδ1 and Vδ2) also worked 315 
well after fixation and permeabilization.  316 
Using a combination of available mAbs, flow cytometry is also useful to monitor the 317 
entire expressed human Vγ repertoire [18]. Such an analysis is based on antibodies 318 
detecting Vγ9 (e.g., clone 7A5) [20], Vγ2/3/4 (clone 23D12) [17, 25], Vγ3/5 (clone 56.3) 319 
[18] and Vγ8 (clone R4.5.1) [26, 27]. As an example, the combination of mAb 56.3 and 320 
23D12 unequivocally identifies γδ T cell clones expressing Vγ3 (56.3+23D12+) and Vγ5 321 
(56.3+23D12-) (Figure 4A, 4B). Moreover, such antibodies are useful for detecting rare 322 
αβ T cells with a trans-rearranged TCR [13, 28]. As shown in Figure 4C, the 56.3-323 
positive clone (established by positive selection of 56.3-positive cells from PBMC) stains 324 
with a pan-αβ T cell antibody (clone IP26) but not with a pan-γδ antibody (clone 11F2). 325 
These cells carry an in-frame Vγ5-Jβ-Cβ trans-rearrangement [18] . 326 
Identification of immune signatures via mass cytometry 327 
A good choice of markers for basic identification of cell populations intended to be 328 




to 40 channels can be acquired in parallel and multidimensional, automated data 330 
analysis is performed. At the time of writing, the only commercially-available pan γδ T 331 
cell antibody suitable for mass cytometry derives from the 11F2 clone. We identified 332 
even greater problems in mass cytometry than those we faced in polychromatic flow 333 
cytometry when using the 11F2 TCR γδ 152 Sm antibody in combination with custom-334 
made B6 TCR Vδ2 141 Pr and TS8.2 Vδ1 FITC antibodies (detected via an anti-FITC 335 
160 Gd). Large proportions of Vδ1 T cells were stained with the pan-γδ TCR antibody, 336 
but none or only a fraction of the Vδ2 T cells (Figure 2C). Steric hindrance caused by 337 
close proximity of the recognized epitopes and size and nature of the antibody tags 338 
might account for these observations. Further testing of the combinations of Vδ1 339 
REA173 and Vδ2 123R3 with the pan-γδ 11F2 antibodies that achieved good resolution 340 
in polychromatic flow cytometry is also warranted in mass cytometry. 341 
 342 
Immunohistochemical detection of tissue-associated γδ T cells  343 
IHC-based tissue analysis enables tissue-infiltrating (γδ) T cell subsets to be analyzed in 344 
the context of their native surroundings, thereby providing a complementary approach to 345 
the above-discussed flow cytometry experiments. In the cancer setting, monitoring the 346 
abundance of tumor-infiltrating γδ T cells and the localization of distinct γδ T cell subsets 347 
can provide a more comprehensive assessment of the tumor status [11]. The best 348 
choice for analysis of the γδ TCR expression was the anti-TCR γ clone γ3.20. As we 349 
previously reported, IHC staining of consecutive paraffin-embedded sections of 350 
pancreatic ductal adenocarcinoma tissue revealed that a large proportion of the 351 




clone γ3.20 is no longer available, but Jungbluth et al. recently reported that the TCR δ 353 
antibody clone H-41 (SC-100289, Santa Cruz) is an alternative for the detection of γδ T 354 
cells in paraffin-embedded tissue [29]. To visualize the distribution of different γδ T cell-355 
subsets, serial tissue sections were stained with our in-house Vγ9 and Vγ2/3/4 356 
antibodies. Analysis of sections from patients with EBV-associated Hodgkin’s lymphoma 357 
showed that most of the γδ T cells from these patients expressed Vγ9, whereas γδ T 358 
cells expressing Vγ2, 3 or 4 were nearly absent (Figure 5A). Furthermore, staining of 359 
cryosections obtained from patients with colon adenocarcinoma using the Vδ1 and 360 
Vγ2/3/4 antibodies revealed that these γδ T cells are enriched in respective 361 
malignancies, as shown for one representative patient (Figure 5B). This indicates that 362 
the Vγ2/3/4 clone 23D12 is also suitable for staining cryosections. 363 
 364 
Concluding remarks 365 
The variety of available reagents for the characterization of γδ T cells is, as the research 366 
field itself, dynamic and growing, but currently still very limited. Here, we outlined a 367 
framework for the phenotypic and functional characterization of human γδ T cells based 368 
on currently available reagents. We are certainly aware that the above-described 369 
antibodies and antibody combinations still have room for improvement. On the part of 370 
the manufacturers, a broader spectrum of fluorophore-antibody conjugates, preferably of 371 
smaller size to minimize potential steric hindrance problems, would be appreciated. One 372 
must also be aware that rare αβ T cells harbor a TCR trans-rearrangement and thus 373 
may express a Vγ rather than a Vβ element. Such αβ T cells stain with anti-Vγ 374 




and Vγ9 [25, 28]. When characterizing γδ T cells in tissue samples the following issues 376 
should be taken into account. First, one should carefully select the enzymes used for 377 
tissue dissociation in order to avoid the loss of certain cell surface markers. Besides 378 
that, sample size and in some cases the low abundance of γδ T cells may be limiting 379 
factors. For γδ T cell immunomonitoring within tumor-infiltrating lymphocytes or tumor-380 
ascites lymphocytes by flow cytometry, the additional use of an anti-CD45 mAb in a 381 
multicolor panel is recommended for precise analysis of the different γδ and αβ T cell 382 
subsets surrounded by many other tumor-associated immune cells and tumor cells 383 
(Oberg et al. this volume). Furthermore, the development of antibodies suitable for 384 
staining paraffin-embedded tissue sections, and antibodies compatible with the 385 
fluorescence microscopy-based MACSima imaging system or the mass cytometry-386 
based Hyperion imaging system could take γδ T cell research to a new level, supporting 387 
the various promising attempts to exploit these remarkable cells for treating infectious 388 
and non-infectious diseases as well as malignancies.  389 
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Figure legends 523 
Figure 1: Magnetic isolation of γδ T cells from PBMCs (A) Representative FACS 524 
plots showing the CD3 compartment pre and post isolation of untouched γδ T cell 525 
preparations. Presented data reflect the reproducibly high purities that are achieved 526 
using kits from either Miltenyi Biotec (Manufacturer M) or STEMCELL Technologies 527 
(Manufacturer S). Viability is reproducibly above 99%. (B) Representative FACS plots of 528 
cell isolates gained with positive selection strategy using kits from Miltenyi Biotec or 529 
STEMCELL Technologies. Shown are target cells in the CD3+ gate. Viability is 530 
reproducibly above 98%. (C) Vδ1-Vδ2- cell fractions from two healthy adult donors are 531 
presented (gated on CD3+ T cells, no contaminating αβ T cells are present). Without the 532 
availability of an anti-human Vδ3 antibody these donors cannot be used for the isolation 533 
of negatively selected pure Vδ2 γδ T cells.  534 
 535 
Figure 2: Phenotypic characterization of γδ T cells via flow cytometry and CyTOF 536 
(A) Phenotypic characterization of the Vδ1 and Vδ2 sub-populations via flow cytometry. 537 
Gating on peripheral, viable, CD3+, lymphocytes showed that the γδ TCR antibody 538 
(clone 11F2) recognized all Vδ1+ (clone REA173) and Vδ2+ (clone 123R3) cells. 539 
Sufficient separation of the sub-populations, gated on γδ TCR+ T cells, was achieved. 540 
(B) Direct and indirect staining of the γδ TCR with the clones 11F2 and IMMU510. The 541 
best separation with the lowest background signal in flow cytometry was achieved with 542 
the biotinylated 11F2 clone. The population was gated on viable, CD3+ lymphocytes. (C) 543 
Characterization of γδ T cell sub-populations by CyTOF in a fixed and permeabilized 544 




CD45+, CD14-, CD33-, CD20-, CD3+ T cells. γδ TCR (clone 11F2; Sm152) stained the 546 
vast majority of the indirectly stained Vδ1+ (clone TS8.2 FITC a Gd160), but none of the 547 
Vδ2+ (clone B6 ; Pr141) γδ T cells.  548 
 549 
Figure 3: Functional characterization of γδ T cells via flow cytometry. (A) Analysis 550 
of cytokine expression in fixed PBMC samples after stimulation with Zoledronate (Vδ2+) 551 
or PMA/Ionomycin (Vδ1+). Vδ1+ and Vδ2+ cells were gated on viable, CD3+, γδ TCR+ 552 
lymphocytes. (B) Proliferation of CD3+γδTCR-, Vδ1+ and Vδ2+ T cells after stimulation 553 
with PHA-L was tracked on the basis of dye dilution using CellTrace Violet. γδ T cell 554 
subpopulations were gated on viable, CD3+, γδ TCR+ lymphocytes. The proliferation 555 
modeling tool included in the FlowJo software enabled a more in-depth analysis of the 556 
proliferative properties. 557 
 558 
Figure 4: Identification of Vγ3 and Vγ5 γδ and αβ T cell clones. Viable cells were 559 
discriminated by gating on lymphocytes (FSC vs. SSC) and by near infra-red live/dead-560 
staining. γδ and αβ T cell clones stained by mAb Vγ3/5 (clone 56.3) were co-labeled 561 
with the mAbs recognizing the αβ TCR (clone IP26), γδ TCR (clone 11F2), Vγ2/3/4 562 
(clone 23D12). (A) Vγ5 γδ clone (IP26-,11F2+,56.3+,23D12-) (B) Vγ3 γδ clone 563 
(IP26,11F2+,56.3+,23D12+); (C) Vγ5 αβ clone (IP26+,11F2-,56.3+,23D12-).  564 
 565 
Figure 5: Distribution of different T cell subsets in EBV-associated Hodgkin´s 566 




tissue sections from patients with EBV-associated Hodgkin´s lymphoma were stained 568 
with γδ TCR (clone γ3.20), Vγ9 (clone 7A5), Vγ2/3/4 (clone 23D12) mAbs as indicated in 569 
one representative donor. (B) Serial cryosections obtained from colon adenocarcinoma 570 
patients were stained with IgG control, Vδ1 (clone R3.12), Vγ2/3/4 (clone 23D12) mAbs 571 
as indicated in one representative patient. IHC staining was performed as described in 572 
the Materials and Methods section.  573 
Table 1: Monoclonal antibody panels for the functional characterization and for tracking 
the proliferation of γδ T cells via flow cytometry 
Specificity  Fluorophore Clone 
Functional characterization  
Dead cells Fixable red  
CD3 BV510 UCHT1 
γδ TCR Biotin + Streptavidin-PE 11F2 
Vδ1  PerCP-Vio700 REA173 
Vδ2 FITC 123R3 
IFN-γ PE-Cy7 B27 
TNF-α Alexa Fluor 700 Mab11 
IL17A BV711 BL168 
CD107a Pacific Blue H4A3 
 
Tracking of proliferation  
Dead cells Fixable red  
CD3 Alexa Fluor 700 UCHT1 
γδ TCR Biotin + Streptavidin-PE 11F2 
Vδ1  APC REA173 
Vδ2 FITC 123R3 
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